View source for 8awm


==RVFV GnH with Fab268 bound==
<StructureSection load='8awm' size='340' side='right'caption='[[8awm]], [[Resolution|resolution]] 3.50&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[8awm]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Rift_Valley_fever_virus Rift Valley fever virus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8AWM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8AWM FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.5&#8491;</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8awm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8awm OCA], [https://pdbe.org/8awm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8awm RCSB], [https://www.ebi.ac.uk/pdbsum/8awm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8awm ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/L7QH21_RVFV L7QH21_RVFV] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
The zoonotic Rift Valley fever virus (RVFV) can cause severe disease in humans and has pandemic potential, yet no approved vaccine or therapy exists. Here we describe a dual-mechanism human monoclonal antibody (mAb) combination against RVFV that is effective at minimal doses in a lethal mouse model of infection. We structurally analyze and characterize the binding mode of a prototypical potent Gn domain-A-binding antibody that blocks attachment and of an antibody that inhibits infection by abrogating the fusion process as previously determined. Surprisingly, the Gn domain-A antibody does not directly block RVFV Gn interaction with the host receptor low density lipoprotein receptor-related protein 1 (LRP1) as determined by a competitive assay. This study identifies a rationally designed combination of human mAbs deserving of future investigation for use in humans against RVFV infection. Using a two-pronged mechanistic approach, we demonstrate the potent efficacy of a rationally designed combination mAb therapeutic.

Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses.,Chapman NS, Hulswit RJG, Westover JLB, Stass R, Paesen GC, Binshtein E, Reidy JX, Engdahl TB, Handal LS, Flores A, Gowen BB, Bowden TA, Crowe JE Jr Nat Commun. 2023 Sep 13;14(1):5650. doi: 10.1038/s41467-023-41171-3. PMID:37704627<ref>PMID:37704627</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 8awm" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Rift Valley fever virus]]
[[Category: Bowden TA]]
[[Category: Hulswit RJG]]
[[Category: Stass R]]